ASCO15: Altor BioScience Corporation Announces Upcoming Data Presentation On Efficacy And Safety Of ALT-801 For Advanced Bladder Cancer At 2015 ASCO Annual Meeting

MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor), a leading developer of cancer immunotherapies, announced today that it will present updated safety and efficacy data from its ongoing Phase 1b/2 study of ALT-801 in combination with gemcitabine and cisplatin in patients with advanced or metastatic chemo-refractory urothelial cancer. The data will be presented in Poster Discussion Session at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 29-June 2 in Chicago.

Help employers find you! Check out all the jobs and post your resume.